Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Additional Site Contact Information +1 (415) 417-3441
NX5948301@nurixtx.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Back

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting

Open to: ALL

Age: 18.0 - N/A

Sutton Plymouth Oxford London Glasgow Leeds London Liverpool Manchester Southampton

Medical Conditions

Lymphoma
Neoplasms
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Waldenstrom Macroglobulinemia

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2022 Jan 2027

Publications

"Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skanland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood. 2023 Mar 30;141(13):1584-1596. doi: 10.1182/blood.2022016934."; "36375120"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Oral NX-5948

Intervention Arm Group : Phase 1a Dose Escalation;Phase 1b Part 1 Cohort 1 in CLL or SLL with prior BTKi and BCL2i;Phase 1b Part 1 Cohort 10 in DLBCL;Phase 1b Part 1 Cohort 11 in FL;Phase 1b Part 1 Cohort 12 in PCNSL/SCNSL;Phase 1b Part 1 Cohort 13 in PCNSL;Phase 1b Part 1 Cohort 14 in first-line WM;Phase 1b Part 1 Cohort 15 in BTKi-naive CLL/SLL;Phase 1b Part 1 Cohort 16 in CLL/SLL with secondary warm autoimmune hemolytic anemia (wAIHA);Phase 1b Part 1 Cohort 17 in CLL/SLL with CNS involvement;Phase 1b Part 1 Cohort 2 in CLL/SLL with non-C481S BTK mutations;Phase 1b Part 1 Cohort 3 in CLL/SLL with prior non-covalent BTKi;Phase 1b Part 1 Cohort 4 in CLL/SLL with TP53 or 17p deletion, 2L, prior BTKi;Phase 1b Part 1 Cohort 5 in CLL/SLL with 2L+, prior BTKi;Phase 1b Part 1 Cohort 6 in MCL;Phase 1b Part 1 Cohort 7 in MZL;Phase 1b Part 1 Cohort 8 in WM (3L+);Phase 1b Part 1 Cohort 9 in WM (2L);Phase 1b Part 2 in CLL or SLL with prior BTKi and BCL-2i;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Marsden NHS Foundation Trust
    Sutton
    SM2 5PT
  • University Hospitals Plymouth NHS Trust
    Plymouth
    PL6 8DH
  • Oxford University Hospitals NHS Foundation Trust
    Oxford
    OX3 7LE
  • Sarah Cannon Research Institute UK
    London
    W1G 6AD
  • The Beatson WOS Cancer Center
    Glasgow
    Scotland
    G12 0YN
  • St. James Hospital
    Leeds
    LS9 7TF
  • St. Bartholomew's Hospital, Barts NHS Trust
    London
    EC1A 7BE
  • Clatterbridge Cancer Center NHS Foundation Trust
    Liverpool
    L7 8YA
  • The Christie NHS Foundation Trust
    Manchester
    M20 4BX
  • University Hospital Southampton NHS Foundation Trust
    Southampton
    SO16 6YD

Additional Site Contact Information +1 (415) 417-3441
NX5948301@nurixtx.com



The study is sponsored by Nurix Therapeutics, Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05131022
Last updated 12 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top